Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-Carnitine in Septic Shock with AKI
NCT02664753Phase 3Terminated
- Sponsor
- CHU Nîmes
- Start
- Mar 2018
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levocarnitine in septic shock and acute kidney injury (AKI), sponsored by CHU Nîmes. Primary endpoint: Mortality at 28 days. Started Mar 2018; status: terminated.
02
Drugs
levocarnitine
03
Conditions
septic shockacute kidney injury (AKI)
Beyond the preview
Go deeper on NCT02664753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02664753.